MAPT and Alzheimer disease: Alzheimer’s disease (AD) is a neurodegenerative disorder leading to a progressive decline in cognitive function that is characterized at the molecular level by β-amyloid (Aβ)-induced synaptic dysfunction, neuronal loss, tau pathology, and oxidative stress (Verkhratsky et al. 2010).